ClinicalTrials.gg
RecruitingNCT07018596NANOPULSE-AFUpdated May 6, 2026

NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System

An interventional study of CellFX nsPFA Cardiac Catheter System in Atrial Fibrillation Paroxysmal, Cardiac Ablation and Cardiac Arrhythmia, sponsored by Pulse Biosciences, Inc.. Recruiting at 1 site in Czechia. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Pulse Biosciences, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
215
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies in Atrial Fibrillation with a site in Czechia — 39 open to participants now, 50 under way, 6 of them phase 3. Atrial Fibrillation · Czechia.

Planned enrollment
74th of 153
215 · median 200
Started
2026
with 10 others
No phase
96 of 184
23 open now
Primary completion
2026-10
later than 19 of 49 live
Registered
168th of 184
by date

Among the 184 studies in Atrial Fibrillation with a site in Czechia, this one is the 74th largest by planned enrollment of the 153 interventional ones that give a count, is one of 11 that started in 2026, is one of 96 with no phase, reaches primary completion later than 19 of the 49 other live ones, and was the 168th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

39 of the 184 studies in Atrial Fibrillation with a site in Czechia are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Atrial Fibrillation with a site in Czechia, or all of them as a file.
02

Study summary

The objective of this study is to demonstrate the safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA) Cardiac Catheter Ablation System in treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF).

Read the detailed description

This study is a prospective, multicenter, non-randomized clinical investigation. Eligible participants with drug-resistant paroxysmal AF who are clinically indicated for a cardiac catheter ablation procedure will undergo nsPFA ablation with the CellFX Cardiac Catheter Ablation System. The primary endpoints will be assessed at 6 months after the ablation procedure.

03

Conditions studied

  • Atrial Fibrillation Paroxysmal
  • Cardiac Ablation
  • Cardiac Arrhythmia

Keywords

  • nsPFA
  • Pulsed Field Ablation
  • nano-PFA
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of recurrent drug-resistant symptomatic paroxysmal AF defined as AF that terminates spontaneously or with intervention within seven (7) days of onset, documented by the following:

    i. Physician's note indicating the presence of AF symptoms and at least two (2) episodes of self-terminating AF within six (6) months prior to enrollment

  • Age 18 through 85 years old (or older than 18 if required by local law)
  • Failure of at least one AAD (class I or III) for AF as evidenced by recurrence of symptomatic AF, or intolerable side effects due to AAD.
  • Participant is willing and capable of providing
  • Received a standard cardiac work up and is an appropriate candidate for an procedure as determined by study investigators

Exclusion criteria

Exclusion Criteria:

  • Left atrial diameter ≥5.5 cm (anteroposterior)
  • Any of the following within 3 months prior to enrollment:

    1. Any cardiac surgery
    2. Myocardial infarction
    3. Percutaneous Coronary Intervention (PCI) / Percutaneous Coronary Intervention (PTCA) or coronary artery stenting
    4. Unstable angina
    5. Pericarditis or symptomatic pericardial effusion
  • Any of the following within 6 months prior to enrollment:

    1. Any cerebral ischemic event (stroke or (TIA)
    2. History of thromboembolic event
  • Prior history of medical procedure involving instrumentation of the left atrium (previous ablation, atrial septal defect (ASD) closure, Left atrial appendage occlusion)
  • Planned Left Atrial Appendage (LAA) closure procedure, Transcatheter Aortic Valve Replacement (TAVR), Mitraclip, Atrial Septal Defect (ASD) or Patent Foramen Ovale (PFO) closure, Triclip or implant of an Implantable Loop Recorder (ILR), permanent pacemaker, biventricular pacemaker, or any implantable cardiac defibrillator (with or without biventricular pacing function) during or for any time during the follow-up period
  • Patient who is not on oral anticoagulation therapy for at least 3 weeks prior to the ablation procedure
  • Documented left atrial (LA) thrombus by imaging within 48 hours of the procedure.
  • Presence of a permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator (with or without biventricular pacing function).
  • Prior diagnosis of pulmonary vein stenosis
  • Valvular cardiac surgical/percutaneous procedure (e.g., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve).
  • Moderate to severe mitral valve stenosis
  • More than moderate mitral regurgitation (i.e., 3+ or 4+ MR)
  • (NYHA) Class III or IV congestive heart failure or documented (LVEF) less than or equal to 35% measured by acceptable cardiac testing (e.g., TTE)
  • History of pulmonary hypertension with pulmonary systolic artery pressure >50 mm Hg, severe or restrictive lung disease
  • Rheumatic heart disease
  • to anticoagulation (i.e., Heparin, Dabigatran, Apixaban, Vitamin K Antagonists such as warfarin)
  • Active systemic infection
  • Hypertrophic or advanced infiltrative cardiomyopathy
  • Atrial myxoma
  • Known reversible causes of AF, including but not limited to uncontrolled hyperthyroidism, severe untreated obstructive sleep apnea, and acute alcohol toxicity
  • History of abnormal bleeding and/or clotting disorder
  • Renal insufficiency with an estimated (eGFR) \< 30 mL/min/1.73 m2, or any history of renal dialysis or renal transplant
  • History of severe chronic gastrointestinal problems involving the esophagus, stomach and/or untreated acid reflux
  • Solid organ or hematologic transplant, or currently being evaluated for an organ transplant
  • Any woman known to be pregnant or breastfeeding, or any woman of who is not on a reliable form of birth regulation method or abstinence
  • Other criteria, which the Investigator determines would make the patient unsuitable to participate (e.g. uncontrolled drug and/or alcohol addiction, congenital disease, fragility)
  • (BMI) > 40.0
  • Participants with any other significant uncontrolled or unstable medical condition (such as uncontrolled brady-arrhythmias, ventricular arrhythmias, hyperthyroidism or significant coagulation disorder)
  • less than one year
  • Current or anticipated participation in any other clinical study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor
  • Unwilling or unable to comply fully with study procedures and follow-up
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
215 participants (estimated)

Study arms

  • Experimental
    nsPFA Cardiac Catheter System Treatment Arm

    Nanosecond Pulsed Field Ablation (nsPFA) technology will be used for ablating cardiac tissue using the CellFX nsPFA Cardiac Catheter System

    Device: CellFX nsPFA Cardiac Catheter System

Interventions

  • DeviceCellFX nsPFA Cardiac Catheter System

    The CellFX nsPFA Cardiac Catheter System includes the nsPFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures to treat arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nanosecond pulses of electrical energy. nsPFA is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the cell's and internal organelles' ability to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).

06

What researchers measure

Primary outcomes

  1. Proportion of participants with freedom from primary safety endpoint

    The primary safety endpoint is freedom from a primary safety endpoint for the following: * Cerebrovascular accident/Stroke * Thromboembolism * Myocardial infarction * Severe Pericarditis (requiring intervention) * Transient ischemic attack * Vagal nerve injury resulting in esophageal dysmotility or gastroparesis * Major vascular access complications * Bleeding * Pulmonary edema * Heart Block * Permanent Phrenic Nerve paralysis * Device or Procedure-related Death * CellFX System-related or PFA procedure-related cardiovascular and/or pulmonary adverse event that prolongs or requires hospitalization for more than 48 hours, excluding recurrent atrial fibrillation/atrial flutter/atrial tachycardia (AF/AFL/AT) * Cardiac tamponade/perforation * Significant acute kidney injury secondary to hemolysis * Pulmonary vein stenosis * Esophageal perforating complications

    Time frame: Within 7 days, 30 days, and 6 months post-ablation procedure

  2. Proportion of participants achieving freedom from treatment failure.

    Acute procedural failure is defined as the inability to isolate all targeted pulmonary veins (PV) (minimally assessed for entrance block and, where assessable, exit block) during the index procedure or PV ablation using a non-study device in the left atrium

    Time frame: 6 months post-ablation

Secondary outcomes

  1. Proportion of participants achieving acute procedural success

    Acute Procedural Success: Ability to isolate all pulmonary veins and no ablation using a non-study device in the left atrium.

    Time frame: Immediately post-ablation procedure

07

Study locations

1 of 1 sites recruiting
  • Na Homolce Hospital
    Prague, Roentgenova 37/2, Czechia
    Recruiting
    • Štěpán Královec · Contact
    • Petr Neuzil, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 6 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 12, 2025
StartActual
Apr 6, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Jan 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07018596
Lead sponsor
Pulse Biosciences, Inc.
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
Apr 6, 2026
Primary completion
Oct 2026 (estimated)
Completion
Jan 2028 (estimated)
Last update
May 6, 2026

Study contacts

Micki Weisman
Contact
micki.weisman@pulsebiosciences.com
510-906-4649
William A. Knape
Contact
bknape@pulsebiosciences.com
510-906-4649
David Kenigsberg, MD
study chair · Pulse Biosciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion